<DOC>
	<DOC>NCT00820079</DOC>
	<brief_summary>Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.</brief_summary>
	<brief_title>ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>diagnosis of typical GERD well controlled on a standard clinical symptoms controlled dose of PPI treatment body mass index â‰¤32 kg/m2 exclusively atypical symptoms of GERD symptoms that have been shown not to be associated with GERD erosive oesophagitis hiatus hernia &gt; 3 cm current diagnosis of coexisting psychiatric disease known clinically significant allergy or known hypersensitivity to drugs pregnant or breastfeeding has received sodium valproate or topiramate within 30 days of Screening has a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Gastroesophageal reflux</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Regurgitation</keyword>
</DOC>